指南与共识妇产影像技术与安全US

超声单元普及子痫前期风险筛查与阿司匹林推荐可行性研究

Feasibility of Universal Screening for Preeclampsia Risk and Aspirin Recommendation in the Ultrasound Unit.
指南 / 共识 · Am J Perinatol · 2023-12-15

研究在孕早期颈项透明层超声检查时,通过自填风险评估表筛查子痫前期风险并劝导中高风险孕妇服用低剂量阿司匹林,20%以上孕妇被筛为高风险,其中94.6%符合条件者接受了劝导,随访中77.9%报告服用阿司匹林,筛查高风险与风险感知正相关,对阿司匹林安全性的担忧负相关。

要点

  • 孕早期颈项透明层超声时自填风险评估可识别约20%子痫前期高风险孕妇(765/3,669)。
  • 高风险孕妇中94.6%(583/616)在超声访视时接受了低剂量阿司匹林劝导。
  • 完成随访者中77.9%(279/358)报告服用低剂量阿司匹林。

核心结论

  • 在颈项透明层超声时评估子痫前期风险并劝导低剂量阿司匹林在超声单元可行,使高风险孕妇阿司匹林使用率良好;该干预可能标准化患者护理并有助于缩小孕产妇健康差异。

研究设计与样本

  • 在常规孕早期颈项透明层超声时用自填风险评估筛查子痫前期临床风险,中高风险者劝导服用低剂量阿司匹林,孕中期超声评估使用情况与风险感知,分析相关因素并比较使用与未使用者的妊娠结局。

诊断标准与关键数值

  • 筛查为子痫前期风险增加者占20%以上(765/3,669)。
  • 风险增加者中67.8%(519/765)未从转诊产科医生处获得低剂量阿司匹林推荐,97人虽被建议但未服用。
  • 符合启动低剂量阿司匹林预防条件者中94.6%(583/616)在超声访视时接受了相应劝导。
  • 完成随访表者占61.4%(358/583),其中77.9%(279/358)报告服用低剂量阿司匹林。

临床应用与阅片要点

  • 筛查为子痫前期风险增加及感知风险增加与低剂量阿司匹林使用正相关,对阿司匹林安全性的担忧与使用负相关。
  • 非洲裔美国/黑人患者和医疗补助(Medicaid)受益者使用低剂量阿司匹林的可能性较低。
  • 使用与未使用低剂量阿司匹林者的妊娠结局相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate the feasibility and impact of using the first-trimester ultrasound visit to identify and counsel women at increased risk of preeclampsia about the benefits of low-dose aspirin (LDA) for preventing preeclampsia. We also assessed patient-reported utilization of LDA, perceived risk for preeclampsia, and clinical outcomes.

STUDY DESIGN: Women presenting for routine first-trimester nuchal-translucency (NT) ultrasounds were screened for clinical preeclampsia risks using a self-administered risk assessment. Women at moderate or high risk for preeclampsia were counseled to take LDA, if not already taking it. LDA utilization and perceived risk for preeclampsia were assessed during the second-trimester ultrasound. Factors associated with LDA utilization were analyzed. Pregnancy outcomes were compared between those who used LDA and those who did not.

RESULTS: Slightly more than 20% of patients (765/3,669) screened at increased risk for developing preeclampsia. Of those, 67.8% (519/765) had not received LDA recommendations from their referring obstetrician and 97 had not been taking LDA despite being advised to do so. Combined, 94.6% (583/616) of these patients eligible to start LDA prophylaxis received the indicated counseling during the ultrasound visit. A total of 61.4% (358/583) of women completed the follow-up form and of those 77.9% (279/358) reported taking LDA. Screening at increased risk for preeclampsia and perception of increased risk were positively associated with LDA utilization, whereas concerns for LDA safety were negatively associated with use. African American/Black patients and Medicaid recipients were less likely to use LDA. Pregnancy outcomes were similar between those who used LDA and those who did not.

CONCLUSION: Assessing preeclampsia risk and counseling patients about LDA at the time of the NT ultrasound are feasible in the ultrasound unit and led to good LDA utilization among women at increased risk for preeclampsia. This intervention may standardize patient care and help close the disparity in maternal health.

KEY POINTS: · A simple intervention captured 2/3 of eligible patients.. · Aspirin utilization rate was good after the intervention.. · Screening high risk for preeclampsia and self-perception of risk correlated with aspirin use..

来源:Am J Perinatol,查看原文。版权归原作者所有。

引用

  1. Pimentel VM, Larrea ADA, Renaud SJ, et al. Feasibility of Universal Screening for Preeclampsia Risk and Aspirin Recommendation in the Ultrasound Unit. Am J Perinatol. 2023. PMID: 38101442. doi:10.1055/s-0043-1777445

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。